Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia: the BREATH-19 Study

NCT04445272 is registered in ClinicalTrials.gov with Fundacion SEIMC-GESIDA as lead sponsor.

NCT NCT04445272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04445272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia: the BREATH-19 Study
Lead sponsor
Fundacion SEIMC-GESIDA
Phase
Phase 2
Overall status
Completed
Start date
May 22, 2020
Completion date
December 23, 2020
Enrollment
495 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19